MedPath

Ocular Imaging With Spectral Domain Optical Coherence Tomography

Not Applicable
Conditions
Healthy
Myopia
Hypermetropia
Interventions
Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
Registration Number
NCT00926549
Lead Sponsor
Yonsei University
Brief Summary

The purpose of this study is to analyze macular retinal thickness and macular volume using the spectral domain - optical coherence tomography (SD-OCT) in normal eyes and in eyes with various ocular diseases.

Detailed Description

Assessment of macular thickness is important for the treatment and follow-up of a variety of ocular diseases. The introduction of optical coherence tomography (OCT) has enabled clinicians to reliably detect small changes in macular thickness and to quantitatively evaluate the efficacy of different therapeutic modalities. In this study using the spectral domain-OCT, we examined the variations of macular retinal thickness and macular volume in normal eyes and in eyes with various ocular diseases.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • normal eyes
  • myopic eyes
  • hypermetropic eyes
Read More
Exclusion Criteria
  • systemic illness
  • cataract
  • previous ocular trauma or surgery(other than cataract surgery or refractive surgeries)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
spectral domain-OCTSpectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)Spectral domain-OCT scanning performed.
Primary Outcome Measures
NameTimeMethod
macular retinal thickness and volume3 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Yonsei University College of Medicine, Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath